David Enloe, CEO of Rose BioSolutions, argues that the traditional outsourcing model in biopharma is becoming outdated, particularly for complex cell and gene therapies. He advocates for a partnership approach where contract development and manufacturing organizations (CDMOs) act as extensions of the sponsor’s team rather than mere vendors. This shift emphasizes the importance of scientific leadership, regulatory expertise, and quality knowledge in addition to manufacturing capacity.
Enloe highlights that early collaboration between sponsors and CDMOs can prevent costly delays and rework by addressing manufacturing and regulatory risks upfront. He notes that trust and transparency are essential for effective partnerships, allowing both parties to share concerns and objectives openly. This evolving model aims to ensure that therapies can be manufactured robustly and at scale, ultimately improving the path from idea to patient.
Source: genengnews.com · Image: "Dr. Kilmer's Standard Herbal Remedies" Residence, consulting rooms, dispensary, and laboratory, Binghamton, N. Y. A trial by jury. Use Dr. Kilmer's Prompt Parilla Liver Pills. – DPLA – 62f70083eb4fc29e5f82eaa36540028e (page 1), Public domain, via Wikimedia Commons
Get started today with Solo access →
